tetano
Editor, Senior Moderator
F1000Res
. 2022 Apr 19;11:434.
doi: 10.12688/f1000research.110268.1. eCollection 2022.
Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain
Javier David Benitez Fuentes[SUP] 1 2 [/SUP], Alicia de Luna Aguilar[SUP] 1 [/SUP], Alejandro Francisco Jimenez Ortega[SUP] 3 [/SUP], Paloma Flores Navarro[SUP] 1 [/SUP], Jorge Bartolomé Arcilla[SUP] 1 [/SUP], Elvira Baos Muñoz[SUP] 4 [/SUP], Alberto Delgado-Iribarren García-Campero[SUP] 4 [/SUP], Sara Gil Useros[SUP] 1 [/SUP], Ignacio Martinez Capella[SUP] 5 [/SUP], Laura Llorente Sanz[SUP] 5 [/SUP], Macarena Torrego Ellacuría[SUP] 5 [/SUP], Pedro Pérez Segura[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. Methods: The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This retrospective cohort study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three-dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect data between April 19, 2021, and December 31, 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study. Results: A total of 93 patients met the inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs followed the opposite pattern (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, p = 0.012, with a higher Eastern Cooperative Oncology Group (ECOG) score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that women had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016). Conclusion: The mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.
Keywords: COVID-19; Cancer; Oncology; SARS-CoV-2; Safety; mRNA-1273 Vaccine.
. 2022 Apr 19;11:434.
doi: 10.12688/f1000research.110268.1. eCollection 2022.
Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain
Javier David Benitez Fuentes[SUP] 1 2 [/SUP], Alicia de Luna Aguilar[SUP] 1 [/SUP], Alejandro Francisco Jimenez Ortega[SUP] 3 [/SUP], Paloma Flores Navarro[SUP] 1 [/SUP], Jorge Bartolomé Arcilla[SUP] 1 [/SUP], Elvira Baos Muñoz[SUP] 4 [/SUP], Alberto Delgado-Iribarren García-Campero[SUP] 4 [/SUP], Sara Gil Useros[SUP] 1 [/SUP], Ignacio Martinez Capella[SUP] 5 [/SUP], Laura Llorente Sanz[SUP] 5 [/SUP], Macarena Torrego Ellacuría[SUP] 5 [/SUP], Pedro Pérez Segura[SUP] 1 [/SUP]
Affiliations
- PMID: 36636471
- PMCID: PMC9816496
- DOI: 10.12688/f1000research.110268.1
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. Methods: The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This retrospective cohort study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three-dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect data between April 19, 2021, and December 31, 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study. Results: A total of 93 patients met the inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs followed the opposite pattern (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, p = 0.012, with a higher Eastern Cooperative Oncology Group (ECOG) score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that women had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016). Conclusion: The mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.
Keywords: COVID-19; Cancer; Oncology; SARS-CoV-2; Safety; mRNA-1273 Vaccine.